Fig. 1
From: Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
Bortezomib resistance is not solely driven by adaptations of the proteasome. a Cell viability of RPMI-8226 wild type (WT) and bortezomib-resistant (BTZ/7 and BTZ/100) cells after a 48-h treatment with increasing concentrations of bortezomib. Results represent % cell viability ± SD compared to non-treated controls of a representative experiment (n = 3). b In gel fluorescence measurements of a representative experiment showing proteasome activity profiles of RPMI-8226 WT, BTZ/7, and BTZ/100 cells after a 1-h incubation with proteasome activity probe Me4BodipyFL-Ahx3L3VS (lower panel). Quantification of gel images, with subunit activity plotted as of total proteasome activity. Results represent averages of 3 independent experiments (upper panel). c Total proteasome activity of RPMI-8226 WT, BTZ/7 and BTZ/100 cells after a 2-h incubation with increasing concentrations of bortezomib, compared to non-treated controls. Results represent quantification of gel images obtained by a 1-h incubation with Me4BodipyFL-Ahx3L3VS. Results represent averages of 3 independent experiments. BTZ = bortezomib